{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Bladder&page=37",
    "query": {
      "condition": "Carcinoma of the Bladder",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 1037,
    "total_pages": 104,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Bladder&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Bladder&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T01:48:51.330Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Bladder Carcinoma",
        "Advanced Lung Non-Small Cell Carcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Melanoma",
        "Advanced Merkel Cell Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Merkel Cell Carcinoma AJCC v8",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage III Merkel Cell Carcinoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Merkel Cell Carcinoma AJCC v8",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IVA Bladder Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Bladder Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plinabulin",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2021-04-14",
      "completion_date": "2025-02-27",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-18T01:48:51.330Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04902040"
    },
    {
      "nct_id": "NCT04604158",
      "title": "Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Cancer Metastatic",
        "Neoplasms",
        "Breast Cancer",
        "Lung Cancer",
        "Glioblastoma",
        "Prostate Cancer",
        "Gynecologic Cancer",
        "Colorectal Cancer",
        "Sarcoma",
        "Kidney Cancer",
        "Bladder Cancer",
        "Lymphoma",
        "Leukemia",
        "Head and Neck Cancer",
        "Pancreas Cancer",
        "Multiple Myeloma",
        "Anxiety",
        "Social Isolation",
        "Stress",
        "Loneliness",
        "Melanoma",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "Elly Mobile Phone Application",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Gillian Gresham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2020-12-02",
      "completion_date": "2024-05-17",
      "has_results": false,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-10-18T01:48:51.330Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04604158"
    },
    {
      "nct_id": "NCT04068896",
      "title": "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Bladder Cancer",
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Head Neck Squamous Cell Carcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "NGM120 30mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 30mg with Gemcitabine and Abraxane",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg with Gemcitabine and Abraxane",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg Q3W",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2019-10-16",
      "completion_date": "2024-01-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-10-18T01:48:51.330Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04068896"
    },
    {
      "nct_id": "NCT02494635",
      "title": "Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Papillary Urothelial Carcinoma",
        "Stage 0a Bladder Urothelial Carcinoma",
        "Stage 0is Bladder Urothelial Carcinoma",
        "Stage I Bladder Cancer With Carcinoma In Situ",
        "Stage I Bladder Urothelial Carcinoma",
        "Stage II Bladder Urothelial Carcinoma",
        "Stage III Bladder Urothelial Carcinoma",
        "Stage IV Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2015-09-16",
      "completion_date": "2019-02-22",
      "has_results": false,
      "last_update_posted_date": "2019-07-08",
      "last_synced_at": "2026-10-18T01:48:51.330Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02494635"
    },
    {
      "nct_id": "NCT03091660",
      "title": "S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage 0 Bladder Urothelial Carcinoma",
        "Stage 0is Bladder Urothelial Carcinoma",
        "Stage I Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "BCG Solution",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG Tokyo-172 Strain Solution",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG Tokyo-172 Strain Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2017-02-24",
      "completion_date": "2026-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-10-18T01:48:51.330Z",
      "location_count": 174,
      "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03091660"
    },
    {
      "nct_id": "NCT00397488",
      "title": "Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Urethral Cancer"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 78,
      "start_date": "2006-09",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2016-01-25",
      "last_synced_at": "2026-10-18T01:48:51.330Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00397488"
    },
    {
      "nct_id": "NCT05241340",
      "title": "Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "Sasanlimab",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Radical Cystectomy + pelvic lymph node dissection + urinary diversion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2022-02-15",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-10-18T01:48:51.330Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05241340"
    },
    {
      "nct_id": "NCT03106610",
      "title": "Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2017-07-07",
      "completion_date": "2018-05-16",
      "has_results": false,
      "last_update_posted_date": "2018-05-24",
      "last_synced_at": "2026-10-18T01:48:51.330Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03106610"
    },
    {
      "nct_id": "NCT00588640",
      "title": "Study of D-Methadone in Patients With Chronic Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pain",
        "Bladder Cancer",
        "Breast Cancer",
        "CNS Cancer",
        "Colon Cancer",
        "Esophageal Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer",
        "Uterine Cancer",
        "Head and Neck Cancer",
        "Eye Cancer",
        "Otorhinolaryngologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "D-methadone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2004-10",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2016-08-10",
      "last_synced_at": "2026-10-18T01:48:51.330Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00588640"
    },
    {
      "nct_id": "NCT05259397",
      "title": "PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "PF-07225570",
          "type": "DRUG"
        },
        {
          "name": "sasanlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-03-24",
      "completion_date": "2022-09-19",
      "has_results": false,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-10-18T01:48:51.330Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05259397"
    }
  ]
}